Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -0.80% is 53% above its 5-year average of -1.68%, around the middle of its 5-year range (-9.45%–4.16%).
As of the fiscal period ended Wednesday, December 31, 2025. 85.43% above its 12-month average of -5.49%.
Annual fiscal-year return on assets; no daily interpolation.
RETURN ON ASSETS (ROA)
-0.80%
RETURN ON ASSETS (ROA) AVG TTM
-5.49%
RETURN ON ASSETS (ROA) AVG 3Y
-1.68%
RETURN ON ASSETS (ROA) AVG 5Y
-1.68%
RETURN ON ASSETS (ROA) AVG 10Y
-0.57%
RETURN ON ASSETS (ROA) AVG 15Y
2.04%
RETURN ON ASSETS (ROA) AVG 20Y
2.26%
CURRENT VS TTM AVG
+85.43%
CURRENT VS 3Y AVG
+52.31%
CURRENT VS 5Y AVG
+52.52%
CURRENT VS 10Y AVG
-41.34%
CURRENT VS 15Y AVG
-139.29%
CURRENT VS 20Y AVG
-135.41%
SECTOR MEDIAN · HEALTHCARE
4.76%
median of 79 covered companies
CURRENT VS SECTOR MEDIAN
-116.81%
vs the sector median at left
Viatris Inc.
Market Cap
$20.55B
Return on Assets (ROA)
-0.80%
TTM Avg
-5.49%
3Y Avg
-1.68%
5Y Avg
-1.68%
Market Cap
$22.03B
Return on Assets (ROA)
18.16%
TTM Avg
16.59%
3Y Avg
14.73%
5Y Avg
13.22%
Market Cap
$18.99B
Return on Assets (ROA)
3.35%
TTM Avg
3.64%
3Y Avg
3.29%
5Y Avg
2.38%
Market Cap
$22.32B
Return on Assets (ROA)
-28.75%
TTM Avg
-24.02%
3Y Avg
-10.32%
5Y Avg
-0.33%
Market Cap
$23.16B
Return on Assets (ROA)
-6.03%
TTM Avg
-3.96%
3Y Avg
9.16%
5Y Avg
17.06%
Market Cap
$16.97B
Return on Assets (ROA)
5.92%
TTM Avg
7.45%
3Y Avg
8.56%
5Y Avg
11.79%
Market Cap
$24.28B
Return on Assets (ROA)
20.48%
TTM Avg
9.54%
3Y Avg
8.43%
5Y Avg
7.44%
Market Cap
$16.41B
Return on Assets (ROA)
23.89%
TTM Avg
21.05%
3Y Avg
19.32%
5Y Avg
16.45%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Viatris Inc. (VTRS) | $20.55B | -0.80% | -5.49% | -1.68% | -1.68% |
| United Therapeutics Corporation (UTHR)vs › | $22.03B | 18.16% | 16.59% | 14.73% | 13.22% |
| Zimmer Biomet Holdings, Inc. (ZBH)vs › | $18.99B | 3.35% | 3.64% | 3.29% | 2.38% |
| Moderna, Inc. (MRNA)vs › | $22.32B | -28.75% | -24.02% | -10.32% | -0.33% |
| STERIS plc (STE)vs › | $22.68B | 7.29% | 6.68% | 4.44% | 4.33% |
| BioNTech SE (BNTX)vs › | $23.16B | -6.03% | -3.96% | 9.16% | 17.06% |
| Hologic, Inc. (HOLX)vs › | $16.97B | 5.92% | 7.45% | 8.56% | 11.79% |
| Incyte Corporation (INCY)vs › | $24.28B | 20.48% | 9.54% | 8.43% | 7.44% |
| Medpace Holdings, Inc. (MEDP)vs › | $16.41B | 23.89% | 21.05% | 19.32% | 16.45% |
| West Pharmaceutical Services, Inc. (WST)vs › | $24.72B | 13.86% | 12.54% | 14.20% | 14.86% |
ROA
-0.8%
ROE
-2.0%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -9.45% |
| 2024-12-31 | -1.53% |
| 2023-12-31 | 0.11% |
| 2022-12-31 | 4.16% |
| 2021-12-31 | -2.31% |
| 2020-12-31 | -1.09% |
| 2019-12-31 | 0.05% |
| 2018-12-30 | 1.08% |
| 2017-12-30 | 1.94% |
| 2016-12-30 | 1.38% |
| 2015-12-30 | 3.81% |
| 2014-12-30 | 5.87% |
| 2013-12-30 | 4.08% |
| 2012-12-31 | 5.37% |
| 2011-12-31 | 4.63% |
| 2010-12-31 | 2.99% |
| 2009-12-31 | 2.15% |
| 2008-12-31 | -1.89% |
| 2007-12-31 | -13.37% |
| 2006-03-31 | 9.87% |
| 2005-03-31 | 9.53% |
| 2004-03-31 | 17.75% |
